A Clinical Isolate of Candida albicans with Mutations in ERG11 (Encoding Sterol 14α-Demethylase) and ERG5 (Encoding C22 Desaturase) Is Cross Resistant to Azoles and Amphotericin B
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
A clinical isolate of Candida albicans was identified as an erg5 (encoding sterol C22 desaturase) mutant in which ergosterol was not detectable and ergosta 5,7-dienol comprised >80% of the total sterol fraction. The mutant isolate (CA108) was resistant to fluconazole, voriconazole, itraconazole, ketoconazole, and clotrimazole (MIC values, 64, 8, 2, 1, and 2 μg ml −1 , respectively); azole resistance could not be fully explained by the activity of multidrug resistance pumps. When susceptibility tests were performed in the presence of a multidrug efflux inhibitor (tacrolimus; FK506), CA108 remained resistant to azole concentrations higher than suggested clinical breakpoints for C. albicans (efflux-inhibited MIC values, 16 and 4 μg ml −1 for fluconazole and voriconazole, respectively). Gene sequencing revealed that CA108 was an erg11 erg5 double mutant harboring a single amino acid substitution (A114S) in sterol 14α-demethylase (Erg11p) and sequence repetition (10 duplicated amino acids), which nullified C22 desaturase (Erg5p) function. Owing to a lack of ergosterol, CA108 was also resistant to amphotericin B (MIC, 2 μg ml −1 ). This constitutes the first report of a C. albicans erg5 mutant isolated from the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Interestingly, the direct target gene of azoles, ERG11 , can only be disrupted in the ERG3 -de fi cient strains or when strains are cultured in media with nystatin or amphotericin B, as the sterols with a C14-methyl group or diols especially for 14-methylergosta-8,24(28)-dien-3 b ,6 a -diol accumulated by ERG3 is lethal in C. albicans .”
From The synthesis, regulation, and functions of sterols in Candida albicans: Well-known but still lots to learn (2016) · cites this paper as [32]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“By using the technology of gene disruption and controlled gene expression, ERG1 , ERG7 , ERG9 , ERG25 , ERG26 , and ERG27 have been proved to be essential, while ERG2 , ERG3 , ERG5 , ERG6 , and ERG24 are considered to be non-essential in ergosterol biosynthesis.”
From The synthesis, regulation, and functions of sterols in Candida albicans: Well-known but still lots to learn (2016) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lower abundance of the enzyme has been observed in polyene-resistant species, which has been attributed to mutations in ERG2 [61,112], ERG3 [51], ERG5 [60], ERG6 [113], and ERG11 [60] genes, which encode enzymes involved in ergosterol synthesis.”
From Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens (2018) · cites this paper as [60]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“there is a report of mutations in other ergosterol biosynthesis genes, such as ERG5, conferring azole resistance in C. albicans, this report is isolated.”
From Molecular and genetic basis of azole antifungal resistance in the opportunistic pathogenic fungus Candida albicans (2020) · cites this paper as [129]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Acquired resistance is also rare, and involves reduced ergosterol biosynthesis and the production of alternative sterols to which amphotericin B has low affinity.”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [64]
Experimental — accuracy not yet measured
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Sanglard, D., Kuchler, K., Ischer, F., Pagani, J. L., Monod, M., & Bille, J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.11.2378 · Cited by 815 · cited 1×
“There has been an increase in research surrounding the potential importance of drug efflux transporters (26, 30) and changes in sterol 14 -demethylase (ERG11 [CYP51]), the target of azole antifungals (10, 12, 13, 14, 25).”
BackgroundSaville, S. P., Lazzell, A. L., Monteagudo, C., & Lopez-Ribot, J. L. (2003) · Eukaryotic Cell · doi:10.1128/ec.2.5.1053-1060.2003 · Cited by 655 · cited 4×
“(B) Sterol intermediates that accumulate with classical azole inhibition of Erg11p; here, the end product is fungistatic 14 -methyl ergosta 8,24(28)-dien-3 ,6 -diol.”
BackgroundInfluentialWhite, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1482 · Cited by 612 · cited 1×
“Several mechanisms can contribute to azole resistance in pathogenic fungi, such as Candida albicans (4, 11, 14, 32, 33).”
BackgroundSanglard, D., Ischer, F., Koymans, L., & Bille, J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.241 · Cited by 465 · cited 2×
“There has been an increase in research surrounding the potential importance of drug efflux transporters (26, 30) and changes in sterol 14 -demethylase (ERG11 [CYP51]), the target of azole antifungals (10, 12, 13, 14, 25).”
BackgroundBaillie, G. S. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.3.397 · Cited by 389 · cited 1×
“Biofilm formation (2) and the possibility for azole sequestration mechanisms (15) have also attracted attention.”
BackgroundKelly, S. L., Lamb, D. C., Kelly, D. E., Manning, N. J., Loeffler, J., Hebart, H., Schumacher, U., & Einsele, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(96)01360-9 · Cited by 351 · cited 2×
“Nonetheless, viable erg3 mutants lacking functional sterol (5,6)-desaturase (encoded by ERG3), and thus ergosterol, have been isolated from the clinic (8, 9, 21).”
BackgroundSelf-citationFranz, R., Kelly, S. L., Lamb, D. C., Kelly, D. E., Ruhnke, M., & Morschhäuser, J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.12.3065 · Cited by 339 · cited 1×
“Several mechanisms can contribute to azole resistance in pathogenic fungi, such as Candida albicans (4, 11, 14, 32, 33).”
BackgroundSelf-citationSanguinetti, M., Posteraro, B., Fiori, B., Ranno, S., Torelli, R., & Fadda, G. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.668-679.2005 · Cited by 319 · cited 1×
“Values above the suggested clinical breakpoints (27) are in boldface.”
BackgroundWhite, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1488 · Cited by 292 · cited 2×
“Several mechanisms can contribute to azole resistance in pathogenic fungi, such as Candida albicans (4, 11, 14, 32, 33).”
Background
Cited by
Items 101–166 of 166
Mechanisms of Drug Resistance in Fungi and Their Significance in Biofilms
Prasad, R., Shah, A. H., & Dhamgaye, S. (2014) · Springer series on biofilms · doi:10.1007/978-3-642-53833-9_4 · Cited by 14
Lv, Q., Qin, Y., Yan, L., Wang, L., Zhang, C., & Jiang, Y. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00218 · Cited by 13
Yoshioka, M., Yamada, K., Yamaguchi, Y., Ogita, A., Fujita, K., & Tanaka, T. (2016) · Microbiology · doi:10.1099/mic.0.000269 · Cited by 13
“Notably, pathogenic fungi with a mutation in the ergosterol biosynthetic pathway not only accumulate a synthetic intermediate instead of ergosterol, but are also resistant to AmB (Martel et al., 2010; Young et al., 2003) in addition to azoles (Martel et al., 2010; Pinjon et al., 2003).”
BackgroundSztafrowski, D., Suchodolski, J., Muraszko, J., Sigler, K., & Krasowska, A. (2019) · Folia Microbiologica · doi:10.1007/s12223-019-00686-3 · Cited by 12
Emerging Role of Sphingolipids in Amphotericin B Drug Resistance
Madaan, K., & Bari, V. K. (2023) · Microbial Drug Resistance · doi:10.1089/mdr.2022.0353 · Cited by 13
“72 Moreover, in other Candida spp., such as C. lusitaniae and N. glabrata inactivation of ERG6 (C-24 sterol methyl-transferase) and ERG2 (C-8 sterol isomerase), involved in AmB resistance, 63,68 in addition, a nonsynonymous mutation in ERG6 (V126F or C198F), and ERG2 (G119S or G122S) resulted in…”
Mahendrarajan, V., & Bari, V. K. (2022) · Mycology: An International Journal on Fungal Biology · doi:10.1080/21501203.2022.2138599 · Cited by 12
“So far, several modes of AmB drug resistance are reported such as the decrease in ergosterol content or mutation in ergosterol biosynthetic pathway genes, which was proposed to be the primary cause responsible for its resistance (Sanglard et al. 2003; Young et al. 2003; Martel et al. 2010).”
BackgroundA 32-Year-Old Man With Ulcerative Mucositis, Skin Lesions, and Nail Dystrophy
Bader, O., Weig, M., Groß, U., Schön, M. P., Mempel, M., & Buhl, T. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir943 · Cited by 12
Self-citationMeng, F., Mi, P., Yu, Z., Wei, W., Gao, L., Ren, J., Li, Z., & Dai, H. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.132756 · Cited by 12
Molecular Techniques and Target Selection for the Identification of Candida spp. in Oral Samples
Magalhães, J., Correia, M. J., Silva, R. M., Esteves, A. C., Alves, A., & Duarte, A. S. (2022) · Applied Sciences · doi:10.3390/app12189204 · Cited by 16
“The ergosterol biosynthetic genes, ERG3 , ERG5 , ERG6 , and ERG11 , are common targets for the detection of antifungal drug resistance to amphotericin B (AMB) [17,162].”
BackgroundA Case for Antifungal Stewardship
Miller, R. A. (2018) · Current Fungal Infection Reports · doi:10.1007/s12281-018-0307-z · Cited by 12
Bozlak, Ç. E. B., Ercan, İ., Işık, E., Şahin, E., Balcioglu, O., Kodedová, M., Zimmermannová, O., Dündar, M., Sychrová, H., & Koç, A. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02268-18 · Cited by 11
Hull, C. M., Purdy, N. J., & Moody, S. C. (2014) · Future Microbiology · doi:10.2217/fmb.13.160 · Cited by 11
What ‘Omics can tell us about antifungal adaptation
Ribeiro, G. F., Denes, E., Heaney, H., & Childers, D. S. (2021) · FEMS Yeast Research · doi:10.1093/femsyr/foab070 · Cited by 11
“…C. glabrata and S. cerevisiae, mutations in ERG genes confer some protection against AmB by depleting ergosterol from the plasma membrane (Geber et al. 1995; Kelly et al. 1996; Sanglard et al. 2003; Vandeputte et al. 2008; Martel et al. 2010; Hull et al. 2012b; Kodedová and Sychrová 2015).”
BackgroundDeciphering the multidrug resistance paradigm in Candida auris
Santana, D. J., Cauldron, N. C., Rogers, P. D., & Cuomo, C. A. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01062-24 · Cited by 10
“Acquired amphotericin B resistance in other Candida species often involves mutations in ergosterol biosynthesis genes ERG2 (161, 162) and ERG6 or combined mutations in ERG11 with ERG3 or ERG5 (163, 164).”
Bohner, F., Papp, C., Takács, T., Varga, M., Szekeres, A., Nosanchuk, J. D., Vágvölgyi, C., Tóth, R., & Gácser, A. (2023) · Journal of Fungi · doi:10.3390/jof9121148 · Cited by 10
“However, clinical isolates of C. albicans accumulating alternative byproducts have previously been found, showing that strains with atypical sterol profiles can be viable even in hostile environments [70–72].”
BackgroundLavergne, R., Albassier, M., Hardouin, J.-B., Álvarez, C., Pagniez, F., Morio, F., Pape, P. L., & Ourliac‐Garnier, I. (2022) · Microorganisms · doi:10.3390/microorganisms10010104 · Cited by 10
“The ergosterol biosynthesis pathway has been described for some fungal pathogens such as Candida albicans [10], Cryptococcus neoformans [11], A.”
BackgroundKordalewska, M., Guerrero, K. D., Mikulski, T. D., Elias, T. N., Garcia‐Rubio, R., Berrío, I., Gardam, D. J., Heath, C. H., Chowdhary, A., Govender, N. P., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.22.465535 · Cited by 9
“albicans isolate was reported 50 to harbor a substitution in ERG11 and a sequence repetition (10 duplicated amino acids) leading 51 to loss of function of ERG5 (C-22 sterol desaturase) (5).”
BackgroundAzole Antifungal Drugs: Mode of Action and Resistance
Garcia‐Rubio, R., Monteiro, M. C., & Mellado, E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.20731-0 · Cited by 9
Abou-Kandil, A., Tröger-Görler, S., Pschibul, A., Krüger, T., Rosin, M., Schmidt, F., Akbarimoghaddam, P., Sarkar, A., Cseresnyés, Z., Shadkchan, Y., et al. (2024) · microLife · doi:10.1093/femsml/uqae024 · Cited by 12
“In Candida species, resistance has been linked to genetic mutations in enzymes involved in er goster ol biosynthesis (Martel et al. 2010 , Vincent et al. 2013 , Ahmad et al. 2019 ).”
Yona, A., & Fridman, M. (2024) · Biochemistry · doi:10.1021/acs.biochem.3c00595 · Cited by 8
Dalhoff, A. (2017) · Clinical Microbiology Open Access · doi:10.4172/2327-5073.1000287 · Cited by 8
Mechanisms of Drug Resistance in Candida albicans
Sanglard, D. (2017) · Springer eBooks · doi:10.1007/978-3-319-50409-4_15 · Cited by 11
Lange, T., Sprague, J. L., Vij, R., Alonso‐Román, R., Jablonowski, N., Radosa, S., Krüger, T., Kniemeyer, O., Hillmann, F., Brakhage, A. A., et al. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1013542 · Cited by 8
“Changes in ergosterol biosynthesis genes such as ERG11 , ERG2 , ERG3 , and ERG5 have been described as mediators of C. albicans ’ resistance to polyene and azole anti-fungals [75,85–87].”
A study of genomic complexity underlying multidrug resistance in Candida auris strains in Thailand
Opassathian, K., Boonmee, N., Swangkaew, S., Jenjaroenpun, P., Wongsurawat, T., Kruasuwan, W., Ngamskulrungroj, P., & Mitrpant, C. (2025) · Scientific Reports · doi:10.1038/s41598-025-25386-6 · Cited by 9
Chauhan, A., Gow, N. A. R., & Prasad, R. (2026) · The Cell Surface · doi:10.1016/j.tcsw.2026.100168 · Cited by 8
Ibe, C., Otu, A. A., & Pohl, C. H. (2025) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2024.2448844 · Cited by 7
“Amino acid substitutions in Erg proteins, including Erg2–6 and Erg11 have been associated with resistance to amphotericin B in Candida [79,80].”
Al-Ali, S., & Al-Judaibi, A. A. (2019) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2019.73004 · Cited by 8
Liang, T., Chen, W., Yang, X., Wang, Q., Wan, Z., Li, R., & Liu, W. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.680749 · Cited by 5
Multidrug- and Cross-Resistant Candida: the Looming Threat
Lackner, M., Martín‐Vicente, A., & Lass‐Flörl, C. (2014) · Current Fungal Infection Reports · doi:10.1007/s12281-014-0210-1 · Cited by 7
Yang, Y., Hou, J., & Luan, J. (2024) · Food and Chemical Toxicology · doi:10.1016/j.fct.2024.114581 · Cited by 4
Zhu, M., Wang, Y., Zhao, J., Shi, Z., Ma, C., Yu, Q., & Li, M. (2024) · Microbiological Research · doi:10.1016/j.micres.2024.127918 · Cited by 5
de Mello, T. P., Ramos, L. S., Andrade-Neto, V. V., Torres-Santos, E. C., Lackner, M., Branquinha, M. H., & dos Santos, A. L. S. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae381 · Cited by 3
Gene Expression Analysis of Key Players Associated with Fluconazole Resistance in Candida albicans
Zhang, H., Xu, Q., Li, S., Ying, Y., Zhang, Z., Zeng, L., Huang, X., & Huang, S. (2019) · Jundishapur Journal of Microbiology · doi:10.5812/jjm.88521 · Cited by 4
“The resistance breakpoint categories of 5-flucytosine, itraconazole, and fluconazole were used according to the CLSI M27-A3 criteria (25) while ketoconazole and clotrimazole were based on previous investigations (26), as shown in Table 1.”
MethodAngelini, J., Ferin, S., Martini, L., Flammini, S., Tascini, C., & Giuliano, S. (2026) · Clinical Microbiology Reviews · doi:10.1128/cmr.00228-25 · Cited by 2
“Similarly, clinical evidence indicates that loss-of-function mutations in ERG5 with the accumulation of ergosta-5,7-dienol, an alternative sterol, may reduce susceptibility to AmB (85).”
Teixeira, M. V. S., Mejía, J. A. A., Ferreira, M. E. D. S., & Furtado, N. A. J. C. (2023) · Antibiotics · doi:10.3390/antibiotics12030509 · Cited by 2
Kubica, S., Szulińska, W., Kruszniewska‐Rajs, C., Kimsa‐Dudek, M., Olender, A., Bogut, A., Szukała, M., Dąbrowski, W., Pietrzak, D., Gagoś, M., et al. (2025) · Folia Microbiologica · doi:10.1007/s12223-025-01298-w · Cited by 2
Bustamante, B., Hidalgo, J. A. M., & Campos, P. E. (2017) · Springer eBooks · doi:10.1007/978-3-319-64113-3_2 · Cited by 3
Samanta, I., & Bandyopadhyay, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815770-1.00011-0 · Cited by 2
Emergence of Multidrug Resistance Microbes: Bacteria, Fungi, and Viruses
Malhotra, N., Kumar, P., Ramakrishnan, S., & Rohaun, S. K. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815080056123020005 · Cited by 2
Wang, Z., Xiong, L., Ma, K., Liu, J., Feng, K., & Peng, Y. (2025) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2025.101597 · Cited by 1
Fine-Scale Chromosomal Changes in Fungal Fitness
Fischer, D., Hube, B., & Brunke, S. (2014) · Current Fungal Infection Reports · doi:10.1007/s12281-014-0179-9 · Cited by 1
Barros, A. G., de Araújo, L. P., da Silveira, N. J. F., & Santos, B. R. (2023) · Natural Resources for Human Health · doi:10.53365/nrfhh/158808 · Cited by 1
Drug resistance in pathogenic species of Candida
Jaiswal, N., & Kumar, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91643-1.00014-4 · Cited by 3
The limit to evolutionary rescue depends on ploidy in yeast exposed to nystatin
Ono, J., Kuzmin, A., Miller, L., & Otto, S. P. (2024) · Canadian Journal of Microbiology · doi:10.1139/cjm-2023-0235 · Cited by 2
“Indeed, resistance in this species is usually observed only after long-term fungicide treatment (Dick et al. 1980; Kelly et al. 1996; Martel et al. 2010; Jensen et al. 2015; Dhasarathan et al. 2021).”
Unravelling novel molecular targets of Thymol and Carvacrol in Candida glabrata
Kumar, D., Ansari, A., Rai, N., & Kumar, N. (2024) · Environment Conservation Journal · doi:10.36953/ecj.27792845 · Cited by 1
“The calcium channel proteins Mid1p and Ecm7p participate in the transport of calcium and are voltage - gated, whereas Erg5p is linked to the formation of ergosterol (Martel et al. , 2010; Kato et al. , 2017).”
BackgroundKaradzas, M. T., Michel, A. H., Mosbach, A., Giannakopoulos, G., McGettigan, R., Scalliet, G., & Kornmann, B. (2025) · eLife · doi:10.7554/elife.105333.1 · Cited by 1
Blosser, S. J. (2013) · Montana State University ScholarWorks (Montana State University)
Mechanisms of Action of Antifungal Agents
Flowers, S. A., & Rogers, P. (2015) · CRC Press eBooks · doi:10.1201/b17871-14
How Pathogens Survive Drug Pressure?
Tiwari, B. K., Kak, G., Sharma, D., & Natarajan, K. (2017) · Springer eBooks · doi:10.1007/978-3-319-48683-3_5
Rodríguez-Leguizamón, G. (2016) · Repositorio Institucional E-DocUR (Universidad Del Rosario) · doi:10.48713/10336_13785
Huang, C.-Y., Chen, Y.-C., Wu-Hsieh, B. A., Fang, J.-M., & Chang, Z.-F. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/466938
An Investigation into Clinically Relevant Determinants of Azole Resistance in Candida albicans
Nishimoto, A. T. (2019) · doi:10.21007/etd.cghs.2019.0486
“12 While relatively few in number compared to isolates containing other more common resistance mechanisms, several mutant ERG3 clinical isolates have been identified, and reportedly possess resistance to the azole antifungals and cross-resistance to the polyene amphotericin B (72, 130, 142-145).”
BackgroundKaradzas, M. T., Michel, A. H., Mosbach, A., Giannakopoulos, G., McGettigan, R., Scalliet, G., & Kornmann, B. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.20.614104
Bohner, F. (2024) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.12031
Karadzas, M. T., Michel, A. H., Mosbach, A., Giannakopoulos, G., McGettigan, R., Scalliet, G., & Kornmann, B. (2025) · eLife · doi:10.7554/elife.105333
Gutiérrez‐Rebolledo, G. A., Pérez-González, M. Z., Sánchez‒Ramos, M., & Cruz‐Sosa, F. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-23998-4.00010-5
Thite, T., Jain, P., Iyer, K. A., Tenchov, R., Sasso, J. M., Balande, U., Maind, A., & Zhou, Q. A. (2025) · ChemRxiv · doi:10.26434/chemrxiv-2025-86lcw
Alam, K. (2014) · University Library - University of Saskatchewan (University of Saskatchewan)
El‐Kirat‐Chatel, S. (2010) · theses.fr (ABES) · doi:10.70675/dc8fbc35zca1bz4040zb334z8c3a1b5787de · Cited by 3
Zhang, D., XiaoXing, L., Zhao, X., Yan, Z., Wang, W., & Dai, G. (2026) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2026.2655675 · Cited by 2
“…azole resistance often stems from amino acid substitutions in erg11 (lanosterol 14-α -demethylase), reducing drug binding affinity, while amphotericin B resistance links to mutations in ergosterol biosynthesis enzymes ( ERG2 , ERG3 , ERG5 , ERG11 ) (Martel et al. 2010a, 2010b; Jensen et al. 2015).”
Emerging Antifungal Resistance in Ocular Infections
de Oliveira, H. C., Tabuse, A. M., Höfling-Lima, A. L., & Rodrigues, A. M. (2026) · Springer eBooks · doi:10.1007/978-3-032-19923-2_3
Micafungin exposure drives multidrug resistance in Clavispora lusitaniaePreprint
Wash, E., Scott, N. E., Metzner, K., Zhou, X., Dasilva, D., de Sá, N. P., Usmani, S. A., Sa, N. F. V. D., Poeta, M. D., & Selmecki, A. M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.29.735437
“Resistance to the azole class of antifungals can be conferred by changes to lipid synthesis (24, 43–48) and/or drug efflux (49, 50).”
Lineage-specific adaptation and resistance in Candida albicans
Fernandes, M. Z., Maldonado, E., Martinez‐de‐Oliveira, J., Rolo, J., & Palmeira-de-Oliveira, A. (2026) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2026.104116
Liu, Y., Qiu, Z., Wang, B., Liu, S., Du, Y., & Long, C.-A. (2026) · Physiological and Molecular Plant Pathology · doi:10.1016/j.pmpp.2026.103543
Metadata
- Authors
- Martel, C. M., Parker, J. E., Bader, O., Weig, M., Gross, U., Warrilow, A. G. S., Kelly, D. E., & Kelly, S. L.
- Affiliations
- Swansea University (GB)
- Universitätsmedizin Göttingen (DE)
- ORCID
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2010-09
- Volume
- 54
- Issue
- 9
- Pages
- 3578-3583
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC2934972
- OpenAlex
- W2162351832
- Cited by
- 165
- References
- 37
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 14 · 2023: 14 · 2022: 9 · 2021: 12 · 2020: 10 · 2019: 18 · 2018: 15 · 2017: 10 · 2016: 9 · 2015: 6 · 2014: 11 · 2013: 6 · 2012: 7
- FWCI
- 3.94
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- GRO (submittedVersion, cc-by)
- Funders
- Engineering and Physical Sciences Research Council
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- Candida albicans, azole resistance, amphotericin B resistance, ERG11, sterol 14α-demethylase, fluconazole, voriconazole, ketoconazole, clotrimazole, itraconazole, multidrug efflux pumps, tacrolimus, FK506, clinical isolates, double mutants
- MeSH terms
- Amphotericin B, Antifungal Agents, Azoles, Candida albicans, Fungal Proteins, Microbial Sensitivity Tests, Mutation, Polymerase Chain Reaction, Drug Resistance, Fungal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.